ArticleGastro hep advances2026
Prevalence of Bile Acid Diarrhea and Effect of Budesonide on the Bile Acid Homeostasis in Flare of Microscopic Colitis.
Article in Gastro hep advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Microscopic colitis (MC) and bile acid diarrhea (BAD) are common causes of chronic watery diarrhea. Retrospective studies suggest that BAD coexists in a subset of patients with MC, but the interplay and therapeutic implications remain unclear. We aimed to determine the prevalence of BAD in patients with an MC flare using biochemical markers, to assess the effects of budesonide on BAD biomarkers, and to correlate with clinical outcomes. Methods: In this prospective multicenter study conducted at 3 Danish secondary care outpatient clinics, 49 patients with an MC flare were treated with budesonide for 6 weeks. 7α-hydroxy-4-cholesten-3-one (C4) levels ≥46 ng/mL defined BAD. C4 allows timely testing but has 47% sensitivity. Fecal bile acids (BAs) and fibroblast growth factor 19, stool habits, and quality of life were evaluated. Results: BAD was diagnosed in 6 (12%; 95% confidence interval, 5%-25%) of 49 patients (C4 range 47-92 ng/mL). Three patients had a gray zone C4 between 33 and 46 ng/mL. Patients with BAD had lower fibroblast growth factor 19 and high levels of primary and total BA in spot stool samples. Budesonide significantly reduced diarrhea and improved health-related quality of life in all patients. In patients with BAD, budesonide normalized stool BA, but C4 levels remained elevated. Conclusion: These data demonstrate that some patients with MC flare have BAD. In patients with MC and BAD, budesonide reduced diarrhea symptoms and normalized stool BA levels but did not improve an underlying dysregulation of BA homeostasis. Clinicians may consider testing for BAD in patients with recurrent MC. Trials on therapies targeting BAD in MC patients are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.